Pfizer protection against Ômicron lasts less for children 5 to 11 years old

Pfizer’s Covid-19 vaccine shows a rapid decline in protection when given to children aged 5 to 11. The conclusion was drawn from a New York University study carried out between December 13, 2021 and January 30 of that same year, the peak of transmission of the Ômicron variant in the United States, with 852,384 fully vaccinated children aged 12 at 17 and 365,502 in the new younger age group also with the full vaccination schedule.

The researchers found that the effectiveness of the vaccine in children fell from 68% in mid-December to 12% in late January. Among adolescents and young people, protection fell from 66% to 51%.

In the essay published on the site MedRxiv, a portal that publishes scientific studies that will undergo peer review, scientists call attention to the dose of the immunizer. “These results highlight the potential need to investigate alternative dosing of vaccines for children and the continued importance of layered protections, including the use of masks, to prevent infection and transmission,” said Researchers.

By decision of the pharmaceutical company and on the basis of tests carried out before the appearance of the Omicron variant of SARS-CoV-2, people aged 5 to 11 years receive a dose of active ingredient equivalent to just over 30% of the quantity received by individual from 12 years.

Even though protection waned, researchers noted that vaccination was 48% effective in preventing the younger age group from being hospitalized, with 73% effective against hospitalization among adolescents last month, according to the data. This was less than 100% and 85% effectiveness against hospitalization for both age groups in mid-December.

Pfizer said it was studying a three-dose schedule of the vaccine in the pediatric population, noting that studies in adults suggest that “people vaccinated with three doses of a Covid-19 vaccine may have a higher degree of protection “.

With information from Reuters

Add Comment